Follow TNGB
RFK Jr.’s HHS Cancels $700M Moderna Bird Flu Vaccine Deal
The Department of Health and Human Services, under the leadership of Robert F. Kennedy Jr., has terminated a $766 million contract with Moderna to develop a vaccine targeting pandemic influenza viruses, including H5N1 bird flu. The decision, announced this week, has sparked debate over the future of vaccine development in the United States.
The canceled contract, awarded through the Biomedical Advanced Research and Development Authority (BARDA), included $176 million granted in July 2024 and an additional $590 million in January 2025. These funds were intended to support the development and late-stage clinical trials of Moderna’s mRNA-1018 vaccine, which uses the same technology as its COVID-19 shots.
Moderna reported positive interim results from an early-stage trial of the vaccine, involving 300 healthy adults, showing a robust immune response and a safe profile. Despite this, HHS stated the project did not meet the necessary scientific or safety standards for continued federal investment, though specifics on the criteria were not disclosed.
Kennedy has previously questioned the safety and efficacy of mRNA vaccines, despite evidence supporting their role in saving millions of lives during the COVID-19 pandemic. His influence as HHS Secretary has raised concerns among public health experts about the direction of federal health policy.
The H5N1 bird flu has infected at least 70 people in the U.S. over the past year, primarily farm workers, with one reported death. Scientists warn that unchecked spread could lead to mutations, potentially increasing the virus’s transmissibility or severity in humans.
The decision to cancel the contract comes amid broader actions by Kennedy, including halting CDC campaigns promoting seasonal flu vaccines and postponing key advisory meetings. Critics argue these moves could undermine public confidence in vaccination programs during a severe flu season.
Moderna’s CEO, Stéphane Bancel, expressed optimism despite the setback, stating the company would seek alternative funding to continue vaccine development. The cancellation has prompted questions about the balance between rigorous oversight and the need for rapid response to emerging health threats.
Public health advocates, such as Amesh Adalja from Johns Hopkins, have called the move a step backward, noting the vaccine’s potential as a critical tool against a possible pandemic. As HHS shifts priorities under Kennedy’s leadership, the debate over vaccine policy and public health preparedness is likely to intensify.
